Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

About this update from Lexicon Pharmaceuticals, Inc.

[{"type":"image","alt":"Lexicon Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Lexicon Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bhkXAP8bO_Q1Z4PDGMz_0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8","width":166,"height":50}},"lazy":false},{"type":"text","content":"SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027","length":78,"tagName":"p"},{"type":"text","content":"$10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851","length":93,"tagName":"p"},{"type":"text","content":"Zynquista on track for NDA resubmission and potential approval in 2026","length":70,"tagName":"p"},{"type":"text","content":"Company presentation January 15 at 12:00 p.m. PT (3:00 p.m. ET)","length":63,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a business and pipeline update at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco.","length":251,"tagName":"p"},{"type":"text","content":"“As we look ahead to 2026, Lexicon stands at the threshold of multiple potential catalysts demonstrating the strength of our pipeline and our cardiometabolic expertise. We have pioneered entirely new classes of investigative treatments for critical unmet medical needs, and advanced them into late-stage development,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “We're executing on multiple fronts to deliver breakthrough therapies for patients. We believe our strategic R&D investments will translate into tangible progress during 2026, driving value for both our shareholders and the patient communities we serve.”","length":652,"tagName":"p"},{"type":"text","content":"“As a result of our efforts in 2025 to reduce our operating expenses and become increasingly efficient in our operations, we ended the year with a strong cash balance sufficient to support the advancement of our programs and achieve key milestones into 2027,” said Scott Coiante, Lex...

More updates from Lexicon Pharmaceuticals, Inc.